Characteristics of doripenem: A new broad-spectrum antibiotic

Drug Design, Development and Therapy

Volumn , Issue 3, 2009, Pages 173-190

  Alvarez Lerma, Francisco ^a   Grau, Santiago ^a   Ferrández, Olivia ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Antimicrobial activity; Clinical efficacy; Doripenem; Pharmacokinetics; Tolerability

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; LINCOMYCIN; MACROLIDE; MEROPENEM; METRONIDAZOLE; PANIPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PLASMA PROTEIN; POLYMYXIN B; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE DERIVATIVE; VALPROIC ACID; VANCOMYCIN;

ABDOMINAL INFECTION; ABDOMINAL SURGERY; AGE DISTRIBUTION; ANAEROBIC BACTERIUM; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTEREMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE CLEARANCE; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HYPERSENSITIVITY; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPEPSIA; EOSINOPHIL COUNT; FLATULENCE; GRAM NEGATIVE AEROBIC RODS AND COCCI; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HEADACHE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INJECTION SITE ERYTHEMA; ISOTOPE LABELING; KIDNEY CLEARANCE; KIDNEY FAILURE; LENGTH OF STAY; LIVER DYSFUNCTION; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYCOSIS; NAUSEA; NONHUMAN; PHLEBITIS; PLASMA PROTEIN BINDING; PNEUMONIA; PREVALENCE; PRURITUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PYELONEPHRITIS; RACE DIFFERENCE; REVIEW; SEIZURE; SEX DIFFERENCE; SIDE EFFECT; THROMBOCYTOPENIA; THRUSH; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VERTIGO; VOMITING; VULVA DISEASE; VULVOMYCOSIS;

EID: 77953105644     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/dddt.s3083     Document Type: Review

References (69)

1. Doribax® (doripenem for injection) package insert. Titusville, NJ: Ortho-McNeil Pharmaceutical IR; 2008.
2. Davies TA, Shang W, Bush K, Flamm RK. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008;52(4):1510-1512.
3. Keam SJ. Doripenem: a review of its use in the treatment of bacterial infections. Drugs. 2008;68(14):2021-2057.
4. Mori M, Hikida M, Nishihara T, Nasu T, Mitsuhashi S. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J Antimicrob Chemother. 1996;37(5):1034-1036. (Pubitemid 26160315)
5. Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother. 2004;48(4):1384-1396. (Pubitemid 38405502)
6. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother. 2004;54(1):144-154.
7. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother. 2004;48(8):3136-3140.
8. Doribax™ (doripenem for injection) for Intravenous Infusion. 2007. Accessed on April 22, 2009. Available from: http://www.fda.gov/cder/foi/label/ 2007/022106lbl.pdf.
9. European Medicines Agency. Annex I: Summary of product characteristics. 2007. Accessed on April 22, 2009. Available from: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/doribax/H-891-PI-en.pdf.
10. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect. 2005;11(12):974-984.
11. Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother. 1998;42(1):94-99. (Pubitemid 28053333)
12. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis. 2005;52(1):71-74.
13. Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother. 2006;50(2):819-821.
14. Chen Y, Garber E, Zhao Q, et al. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2005;49(6):2510-2511. (Pubitemid 40734491)
15. Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diagn Microbiol Infect Dis. 2009;63(4):415-425.
16. Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis. 2009;63(4):426-433.
17. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother. 2004;48(4):1313-1319. (Pubitemid 38405487)
18. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-2006. J Antimicrob Chemother. 2008; 62(Suppl 2):ii41-ii54.
19. Watanabe A, Takahashi H, Kikuchi T, et al. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy. 2000;46(3):184-187. (Pubitemid 30209751)
20. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-2006. J Antimicrob Chemother. 2008;62(Suppl 2):ii55-ii63.
21. Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother. 2008;52(12):4388-4399.
22. Marti S, Sanchez-Cespedes J, Alba V, Vila J. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int J Antimicrob Agents. 2009;33(2):181-182.
23. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J Antimicrob Chemother. 2005;55(6):944-949.
24. Wexler HM, Engel AE, Glass D, Li C. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother. 2005;49(10):4413-4417. (Pubitemid 41401003)
25. Snydman DR, Jacobus NV, McDermott LA. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. Antimicrob Agents Chemother. 2008;52(12):4492-4496.
26. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob Agents Chemother. 2008;52(2):761-766.
27. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother. 2007;51(8):2716-2719.
28. Mikamo H, Izumi K, Hua YX, Hayasaki Y, Sato Y, Tamaya T. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. J Antimicrob Chemother. 2000;46(3):471-474. (Pubitemid 30706054)
29. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027-1052.
30. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother. 2004;48(8):3086-3092. (Pubitemid 38989178)
31. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2000;44(12):3322-3327.
32. Pumbwe L, Glass D, Wexler HM. Efflux pump overexpression in multiple-antibiotic-resistant mutants of Bacteroides fragilis. Antimicrob Agents Chemother. 2006;50(9):3150-3153.
33. Ishii Y, Galleni M, Ma L, Frere JM, Yamaguchi K. Biochemical characterisation of the CTX-M-14 beta-lactamase. Int J Antimicrob Agents. 2007;29(2):159-164.
34. Davies TA, Shang W, Bush K, Flamm RK. Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x. J Antimicrob Chemother. 2008;61(3):751-753. (Pubitemid 351321159)
35. Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis. 2006;55(3):241-243.
36. Credito KL, Ednie LM, Appelbaum PC. Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. Antimicrob Agents Chemother. 2008;52(1):365-373.
37. Tsuji M, Matsuda H, Miwa H, Miyazaki S. Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: comparison of in vitro and animal models. J Antimicrob Chemother. 2003;51(2):353-359. (Pubitemid 36231156)
38. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother. 2001;45(1):13-22. (Pubitemid 32039087)
39. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005;49(9):3944-3947.
40. Andes DR, Craig WA. In vivo pharmacodynamic activity of a new carbapenem, doripenem (DOR), against multiple bacteria in a murine thigh infection model. Chicago, IL: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003, Sep 13-17.
41. Kim A, Banevicius MA, Nicolau DP. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother. 2008;52(7):2497-2502. (Pubitemid 351915681)
42. Katsube T, Yano Y, Yamano Y, Munekage T, Kuroda N, Takano M. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model. J Pharm Sci. 2008;97(9):4108-4117.
43. Yano Y, Oguma T, Nagata H, Sasaki S. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci. 1998;87(10):1177-1183. (Pubitemid 28455605)
44. Katsube T, Yamano Y, Yano Y. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J Pharm Sci. 2008;97(4):1606-1614.
45. Nagasawa Z, Kusaba K, Aoki Y. Susceptibility of clinical isolates of Pseudomonas aeruginosa in the Northern Kyushu district of Japan to carbapenem antibiotics, determined by an integrated concentration method: evaluation of the method based on Monte Carlo simulation. J Infect Chemother. 2008;14(3):238-243. (Pubitemid 351875923)
46. Ikawa K, Morikawa N, Uehara S, et al. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents. 2009;33(3):276-279.
47. Wagenlehner FM, Wagenlehner C, Redman R, Weidner W, Naber KG. Urinary bactericidal activity of doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Antimicrob Agents Chemother. 2009;53(4):1567-1573.
48. Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. Pharmacokinetic- pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis. 2009;63(4):409-414.
49. Ikawa K, Morikawa N, Urakawa N, Ikeda K, Ohge H, Sueda T. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother. 2007;60(6):1395-1397. (Pubitemid 350168341)
50. Hori T, Nakano M, Kimura Y, Murakami K. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo. 2006;20(1):91-96. (Pubitemid 43103722)
51. Cirillo I, Mannens G, Janssen C, et al. Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother. 2008;52(10):3478-3483.
52. Cirillo I, Redman R, Vaccaro N, et al. Pharmacokinetics of doripenem in subjects with varying degrees of renal impairment. Washington, DC: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America; 2008, Oct 25-28.
53. Nakajima Y, Mizobuchi M, Nakamura M, et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos. 2004;32(12):1383-1391. (Pubitemid 39564558)
54. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology. 2006;222(1-2):114-124. (Pubitemid 44275125)
55. Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother. 2005;11(5):259-261. (Pubitemid 41570025)
56. Psathas PA, Kuzmission A, Ikeda K, Yasuo S. Stability of doripenem in vitro in representative infusion solutions and infusion bags. Clin Ther. 2008;30(11):2075-2087.
57. Brammer MK, Chan P, Heatherly K, et al. Compatibility of doripenem with other drugs during simulated Y-site administration. Am J Health Syst Pharm. 2008;65(13):1261-1265. (Pubitemid 351898361)
58. Réa-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin. 2008;24(7):2113-2126.
59. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36(4):1089-1096.
60. Gilbert D. 'The truth, if it exists, is in the details'. Crit Care Med. 2008;36(4):1368-1369.
61. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther. 2008;30(5):868-883. (Pubitemid 351799866)
62. Owens RC, Jr. An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in? Crit Care. 2008;12(Suppl 4):S3.
63. Thye DA, Kilfoil T, Leighton A, Wikler M. Doripenem: a phase 1 study to evaluate safety, tolerability and pharmacokinetics in a Western healthy volunteer population. Chicago, IL: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003, Sep 14-17.
64. Saito A, Inamatsu T, Shimada J. Clinical studies of S-4661, new parenteral carbapenem antibiotic, in chronic respiratory tract infections. Toronto, Canada: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997, Sep-Oct 28-31
65. Floren L, Wikler M, Kilfoil T, Ge Y. A phase I, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects. Washington, DC: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004, Oct-Nov 30-32
66. Sodhi M, Axtell SS, Callahan J, Shekar R. Is it safe to use carbapenems in patients with a history of allergy to penicillin? J Antimicrob Chemother. 2004;54(6):1155-1157. (Pubitemid 40136760)
67. Prescott WA Jr, DePestel DD, Ellis JJ, Regal RE. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin Infect Dis. 2004;38(8):1102-1107.
68. McConnell SA, Penzak SR, Warmack TS, Anaissie EJ, Gubbins PO. Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy. Clin Infect Dis. 2000;31(6):1512-1514.
69. Merchant S, Gast C, Nathwani D, et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther. 2008;30(4):717-733. (Pubitemid 351680488)